Leerink Partnrs Comments on Bruker Co.’s Q2 2024 Earnings (NASDAQ:BRKR)

Bruker Co. (NASDAQ:BRKR) – Stock analysts at Leerink Partnrs dropped their Q2 2024 earnings estimates for shares of Bruker in a note issued to investors on Thursday, May 2nd. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings of $0.54 per share for the quarter, down from their prior forecast of $0.59. The consensus estimate for Bruker’s current full-year earnings is $2.82 per share. Leerink Partnrs also issued estimates for Bruker’s Q3 2024 earnings at $0.78 EPS, Q4 2024 earnings at $0.98 EPS, FY2024 earnings at $2.83 EPS, Q1 2025 earnings at $0.63 EPS, Q2 2025 earnings at $0.72 EPS, Q3 2025 earnings at $0.90 EPS, Q4 2025 earnings at $1.20 EPS and FY2026 earnings at $4.02 EPS.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Thursday, May 2nd. The medical research company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.07. The company had revenue of $721.70 million for the quarter, compared to analysts’ expectations of $729.88 million. Bruker had a return on equity of 27.31% and a net margin of 13.38%. The firm’s revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.64 earnings per share.

Several other research analysts also recently weighed in on BRKR. JPMorgan Chase & Co. raised shares of Bruker from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $60.00 to $90.00 in a research report on Wednesday, February 14th. Citigroup upped their price target on Bruker from $80.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th. The Goldman Sachs Group raised their price objective on Bruker from $66.00 to $74.00 and gave the stock a “sell” rating in a research report on Wednesday, April 10th. UBS Group upped their target price on Bruker from $94.00 to $102.00 and gave the company a “buy” rating in a report on Friday, March 1st. Finally, Stifel Nicolaus raised their price target on shares of Bruker from $63.00 to $81.00 and gave the stock a “hold” rating in a report on Wednesday, February 14th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, Bruker currently has a consensus rating of “Moderate Buy” and a consensus target price of $84.86.

Bruker Trading Up 2.5 %

Shares of BRKR opened at $74.33 on Monday. The business’s 50-day moving average price is $86.98 and its 200 day moving average price is $75.44. The company has a current ratio of 1.81, a quick ratio of 0.91 and a debt-to-equity ratio of 0.95. The stock has a market capitalization of $10.80 billion, a P/E ratio of 27.03, a P/E/G ratio of 1.73 and a beta of 1.22. Bruker has a 1-year low of $53.79 and a 1-year high of $94.86.

Institutional Investors Weigh In On Bruker

Hedge funds have recently bought and sold shares of the company. Lindbrook Capital LLC boosted its stake in Bruker by 68.2% during the 4th quarter. Lindbrook Capital LLC now owns 360 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 146 shares during the period. Rise Advisors LLC bought a new position in Bruker during the first quarter worth $27,000. Neo Ivy Capital Management acquired a new position in Bruker during the 4th quarter valued at $30,000. VisionPoint Advisory Group LLC boosted its holdings in Bruker by 145.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 512 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 303 shares during the period. Finally, GAMMA Investing LLC bought a new position in shares of Bruker during the 4th quarter worth about $33,000. 79.52% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Bruker news, Director Hermann Fritz Requardt sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $90.06, for a total transaction of $1,350,900.00. Following the completion of the sale, the director now owns 23,147 shares of the company’s stock, valued at $2,084,618.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 28.30% of the stock is currently owned by corporate insiders.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, March 15th. Stockholders of record on Friday, March 1st were issued a dividend of $0.05 per share. The ex-dividend date was Thursday, February 29th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.27%. Bruker’s dividend payout ratio is currently 7.27%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.